Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Strontium-89

Known as: Strontium Sr-89, strontium (89Sr) chloride, strontium 89 
A radioisotope of strontium, a heavy metal found naturally as a non-radioactive element. With a half-life of 50 days, strontium-89 is a beta emitter… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (3)

MetastronStrontium-89 chloridestrontium chloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Palliative radiotherapy in the treatment of skeletal metastases
Two‐third of patients with metastatic cancer suffer from pain. Pain originating from skeletal metastases is the most common form… Expand
Highly Cited
2001
Highly Cited
2001
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
PURPOSE Plasma vascular endothelial growth factor (VEGF) levels are significantly elevated in patients with hormone-refractory… Expand
  • table 2
  • table 1
  • table 3
Highly Cited
2001
Highly Cited
2001
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
BACKGROUND Prostate carcinoma is linked to osteoblastic metastasis. We therefore investigated the value of bone-targeted… Expand
Review
1997
Review
1997
Development, differentiation, and maturation of Kupffer cells
Primitive macrophages first develop in the murine and human yolk sac and then differentiate into fetal macrophages. Primitive or… Expand
Highly Cited
1996
Highly Cited
1996
Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
  • N. Deb, M. Goris, +6 authors S. Knox
  • Clinical cancer research : an official journal of…
  • 1996
    • Corpus ID: 23105335
A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory… Expand
  • table 1
  • table 2
  • table 3
  • table 5
  • table 6
Review
1995
Review
1995
Strontium 89 therapy for the palliation of pain due to osseous metastases.
OBJECTIVE To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with… Expand
Highly Cited
1994
Highly Cited
1994
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.
From 1988 to 1991, 284 patients with prostatic cancer and painful bone metastases were treated with either radiotherapy or… Expand
  • table I
  • figure 1
  • table 2
  • figure I
  • figure 2
Highly Cited
1993
Highly Cited
1993
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
PURPOSE A large proportion of the practice of radiotherapy in the management of metastatic adenocarcinoma of the prostate is… Expand
Highly Cited
1985
Highly Cited
1985
Strontium-89 therapy for the pain of osseous metastases.
A Phase I and II study has been conducted of the safety and efficacy of 89Sr (injected i.v. as the chloride) to alleviate bone… Expand
Highly Cited
1982
Highly Cited
1982
Resident macrophage proliferation in mice depleted of blood monocytes by strontium-89.
The capacity of resident peritoneal macrophages and alveolar macrophages for self-renewal was studied in CD-1 mice depleted of… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE